UCB (STU:UNC) Institutional Ownership: 36.84% (As of Aug. 02, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:UNC UCB SA STU:UNC
89 GF Score
Price €223.60
GF Value €251.32
Valuation Modestly Undervalued
View Full Analysis

What is UCB Institutional Ownership?

UCB STU:UNC +2.99% 89 Institutional Ownership is 36.84% as of Aug. 02, 2026. GuruFocus rates STU:UNC with a GF Score™ of 89/100 and a GF Value™ of €251.32 (Modestly Undervalued).

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, UCB's institutional ownership is 36.84%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, UCB's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, UCB's Float Percentage Of Total Shares Outstanding is 0.00%.

UCB Institutional Ownership Historical Data

* Premium members only.

The historical data trend for UCB's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

UCB Institutional Ownership Chart

UCB Historical Data

The historical data trend for UCB can be seen below:

2025-08-31 2025-09-30 2025-10-31 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 34.81 35.04 35.76 36.42 36.57 36.24 36.67 37.08 36.54 36.84
STU:UNC
89GF Score
UCB SA STU:UNC
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

UCB Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 36.84% mean?
UCB (STU:UNC) has a Institutional Ownership of 36.84% as of Aug. 02, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on UCB and its competitors.
Is UCB's Institutional Ownership too high?
UCB's current Institutional Ownership is 36.84%. Overall, UCB has a GF Score™ of 89/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does UCB's Institutional Ownership compare to VRTX and REGN?
UCB's Institutional Ownership of 36.84% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on UCB and its competitors. UCB's current Institutional Ownership is 36.84%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UCB stock overvalued right now?
Based on GuruFocus' analysis, UCB (STU:UNC) is currently considered Modestly Undervalued. The stock's GF Value™ is €251.32, compared to a current price of €223.60 — trading 11% below its estimated fair value. The current Institutional Ownership is 36.84%. UCB's overall GF Score™ is 89/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For UCB (STU:UNC), the current Institutional Ownership is 36.84% as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is UCB (STU:UNC) Overvalued in 2026?

Based on GuruFocus' analysis, UCB stock appears to be undervalued. The current stock price of €223.60 is trading 11% below its estimated GF Value™ of €251.32. GuruFocus considers UCB to be Modestly Undervalued.

Key valuation signals for STU:UNC:

  • Institutional Ownership: 36.84%
  • GF Value™: €251.32 vs. price of €223.60 (11% below fair value)
  • GF Score™: 89/100

No single metric tells the full story. See the STU:UNC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

UCB Business Description

Address Allee de la Recherche, 60, Brussels, BEL, B-1070
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome), and Kygevvi (rare mitochondrial disease).
89GF Score

Get the complete analysis for STU:UNC

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€223.60
Price
€251.32
GF Value